Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

BACKGROUND: Arterial stiffness is emerging as an independent risk factor for the development of chronic kidney disease. The sodium glucose co-transporter 2 (SGLT2) inhibitors, which lower serum glucose by inhibiting SGLT2-mediated glucose reabsorption in renal proximal tubules, have shown promise in...

Descripción completa

Detalles Bibliográficos
Autores principales: Aroor, Annayya R., Das, Nitin A., Carpenter, Andrea J., Habibi, Javad, Jia, Guanghong, Ramirez-Perez, Francisco I., Martinez-Lemus, Luis, Manrique-Acevedo, Camila M., Hayden, Melvin R., Duta, Cornel, Nistala, Ravi, Mayoux, Eric, Padilla, Jaume, Chandrasekar, Bysani, DeMarco, Vincent G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065158/
https://www.ncbi.nlm.nih.gov/pubmed/30060748
http://dx.doi.org/10.1186/s12933-018-0750-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065158/
https://www.ncbi.nlm.nih.gov/pubmed/30060748
http://dx.doi.org/10.1186/s12933-018-0750-8

Ejemplares similares